期刊文献+

儿童骨髓增生异常综合征28例临床分析 被引量:3

Clinical analysis of 28 cases of pediatric myelodysplastic syndrome
原文传递
导出
摘要 目的探讨儿童骨髓增生异常综合征(MDS)的临床特点、诊断及治疗。方法回顾性分析2006年1月至2012年3月确诊的28例MDS患儿的临床症状、体征、实验室检查、治疗及疾病转归。结果患儿临床表现主要为贫血(96%)、出血(68%)、发热(68%)或肝脾肿大(61%)。3例(11%)患儿分别转变为急性单核细胞白血病(M5)、红白血病(M6)、急性巨核细胞白血病(M7),转为白血病的时间为1~2个月。患儿骨髓增生程度以活跃和明显活跃为主,病态造血以一系和二系病态为主;铁代谢存在明显紊乱;染色体异常核型检出率为45%,以数量异常为主;T细胞、B细胞、NK细胞总数减低,Th细胞表达减低,Ts细胞表达增高,Th/Ts比值倒置。8例患儿确诊后即放弃治疗;8例仅予对症支持治疗,其中1例失访,1例疾病稳定,6例疾病进展;诱导分化和刺激骨髓造血各1例,均发生疾病进展;10例行化疗,其中2例单药化疗,骨髓均无缓解,另8例联合化疗,其中4例骨髓部分缓解或完全缓解。结论儿童MDS具有临床表现不典型、转为白血病风险高的特点;骨髓增生程度以活跃为主;病态造血以一系和二系病态为主;染色体畸变以数量异常为主;铁代谢明显紊乱,细胞免疫异常。多药联合化疗可延缓病程。 Objective To explore the clinical features, diagnosis and treatment of pediatric myelodysplastic syndrome (MDS). Methods Twenty-eight children with MDS between January 2006 and March 2012 were enrolled in the study. Clinical symptoms, signs, laboratory examinations, treatment and outcomes were retrospectively studied. Results Anemia (96%), bleeding (68%), fever (68%) and hepatosplenomegaly (61%) were main clinical manifestaions in the 28 patients. Three cases (11%) converted into acute monocytic leukemia (M5), erythroleukemia (M6) or acute megakaryocytic leukemia (M7) one to two months later. Bone marrow proliferation mainly demonstrated as active or obviously active. One or two lineages of hematopoietic dysplasia were mostly observed in all 28 cases and obvious iron metabolism disorders were found in these patients. Cytogenetic abnormalities were detected in 45% of the 28 cases, most of which were numeral chromosome abnormalities. T cell, B cell and NK cell numbers decreased, Th cell numbers decreased, Ts cell numbers increased and Th/Ts inversed. Eight cases gave up treatment when confirmed. Of the 8 cases receiving symptomatic and supportive treatment alone, one was lost, one showed disease stability, and the remaining 6 cases showed disease progression. One patient who underwent induced differentiation and one who received hematopoietic therapy showed disease progression. Ten patients underwent chemotherapy. Two cases had no bone marrow remission after single agent chemotherapy. Of the 8 cases who underwent muhi-drug combination chemotherapy, 4 cases achieved partial or complete ,'emission of bone marrow. Conclusions Pediatric MDS is characterized by a lack of typical clinical manifestations, and a high rate of conversion to leukemia. Bone marrow proliferation is mainly active in children with MDS. One or two lineages of hematopoietic dysplasia is common. Among the cytogenetic abnormalities, numeral chromosome abnormalities are common. Obvious iron metabolism disorders and abnormal cellular immunity are found in children with MDS. Multi-drug combination chemotherapy appears to slow the course of the disease.
出处 《中国当代儿科杂志》 CAS CSCD 北大核心 2013年第7期514-518,共5页 Chinese Journal of Contemporary Pediatrics
关键词 骨髓增生异常综合征 临床特点 治疗 儿童 Myelodysplastie syndrome Clinical feature Treatment Child
  • 相关文献

参考文献20

  • 1Passmore S J, Chessells JM, Kempski H, Hann IM, Brownbill PA Stiller CA. Paediatric myelodysplastic syndromes and juvenile my elomonocytic leukaemia in the UK : a population-based study of in cidence and survival[J]. Br J Haematol, 2003, 121 (5) : 758 767.
  • 2Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases [J]. Leukemia, 2003, 17(2) : 277-282.
  • 3Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Poiwit A, et al. The 2008 revision of the World Health Organization(WHO) classification of myeloid neoplasms and acute leukemia : rationale and important changes [J]. Blood, 2009, 114 (5) :937-951.
  • 4无,吴德沛,阮长耿.骨髓增生异常综合征诊断与治疗专家共识[J].中华血液学杂志,2012,33(4):347-352. 被引量:75
  • 5姚玉前,戴碧涛.骨髓增生异常综合征流行病学的研究进展[J].儿科药学杂志,2012,18(4):52-55. 被引量:10
  • 6Gologan R. Epidemiological data on myelodysplastic syndrome patients under 50 years in a single center of Romania [ J ]. Leuk Res, 2010, 34(11) : 1442-1446.
  • 7庞菊萍,王赛娟,孙熠,文金全,王华,刘安生.小儿骨髓增生异常综合征34例分析[J].中国小儿血液,2004,9(4):160-162. 被引量:2
  • 8聂玲,李磷,杨艺红,张战强,于明华,徐泽锋,郝玉书,肖志坚.骨髓增生异常综合征患者铁代谢状况及其对预后的影响[J].中华血液学杂志,2009,30(1):50-53. 被引量:3
  • 9Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan [ J ]. Leukemia, 2001, 15 ( 11 ) : 1713-1720.
  • 10何海龙,柴忆欢,何军,朱玲琍.儿童骨髓增生异常综合征细胞遗传学研究及临床意义[J].临床儿科杂志,2006,24(11):896-898. 被引量:1

二级参考文献75

共引文献110

同被引文献31

  • 1Yang L, Mailloux A, Rollison DE, et al. Naive T -cells in myelodys- plastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency[ J]. Leukemia, 2013,27 (4) :897 - 906.
  • 2Attar EC, Amrein PC, Fraser JW, et al. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelo- dysplastic syndromes (MDS) and acute myeloid leukemia (AML) [ J]. Leuk Res, 2013,37(9) :1016 - 1020.
  • 3Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes : update of SIE, SIES, GITMO practice guidelines [J]. Leuk Res, 2010,34(12) :1576 - 1588.
  • 4Alien SL, Kolitz JE, Lundberg AS, et al. Phase I trims of amonafide as monotherapy and in combination with eytarabine in patients with poor - risk acute myeloid leukemia [ J]. Leuk Res, 2010,34(4) :487 -491.
  • 5Cheson BD, Greenberg PL, Bennett JM, el al. Clinical pplication and proposal for modification of the International Working Group ( IWG ) re- sponse criteria in myelodysplasia [ J ]. Blood, 2006,108 (2) :419 - 425.
  • 6Yoshimi A, Strahm B, Baumann I, et al. Hematopoietic stem cell transplantation in children and young adults with secondary myelodys- plastic syndrome and acute myelogenous leukemia after aplastic anemia [J]. Biol Blood Marrow Transplant, 2014,20(3) :425 -429.
  • 7Potter VT, Krishnamurthy P, Barber LD, et al. Long - term outcomes of alemtuzumab - based reduced - intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelog- enous leukemia secondary to myelodysplastic syndrome [ J ]. Biol Blood Marrow Transplant, 2014,20 ( 1 ) : 111 - 117.
  • 8Itzykson R, Th6pot S, Quesnel B, et al, Prognostic factors for response and overall survival in 282 patients with higher - risk myelodysplastic syndromes treated with azacitidine [ J ]. Blood, 2011,117 ( 2 ) : 403 - 411.
  • 9F enaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher - risk myelodysplastic syndromes : azaciti- dine compared With low dose ara - C [ J]. Br J Haematol, 2010, i49 (2) :244 -249.
  • 10陈涛,肖溶,杨建和,姜乃可,周民.骨髓增生异常综合征预后因素分析[J].临床血液学杂志,2011,24(4):400-403. 被引量:10

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部